MEIJI SEIKA PHARMA
Meiji Seika Pharma engages in the manufacturing and sales of ethical pharmaceuticals, agricultural chemicals and veterinary drugs.
MEIJI SEIKA PHARMA
Industry:
Manufacturing Medical Pharmaceutical Sales
Founded:
1916-10-09
Status:
Active
Similar Organizations
Arich Enterprise
Arich Enterprise is engaged in the manufacturing, promotion, logistics and sale of pharmaceutical products for medical industry.
Binh Dinh Pharmaceutical & Medical Equipment
Binh Dinh Pharmaceutical & Medical Equipment engages in the manufacture and sale of pharmaceutical products.
Desh Rakshak Aushdhalaya Ltd
Desh Rakshak Aushdhalaya is engaged in manufacture of Ayurvedic pharmaceuticals, medicinal, herbal and botanical products.
KPX LifeScience
KPX LifeScience is engaged in the production and sale of pharmaceutical and agricultural raw materials
Mediplantex National Pharmaceutical
Mediplantex National Pharmaceutical is engaged in the manufacture and sale of pharmaceutical products and raw materials
Medridge
Medridge specializes in the design, manufacturing and sales of pharmaceutical research equipment and medical equipment.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-06-04 | Curadim Pharma | Meiji Seika Pharma investment in Venture Round - Curadim Pharma | 1.33 B JPY |
| 2015-01-30 | Solasia Pharma | Meiji Seika Pharma investment in Corporate Round - Solasia Pharma | 900 M JPY |
More informations about "Meiji Seika Pharma"
Meiji Seika Pharma - Wikipedia
Meiji Seika Pharma Co., Ltd. (Meiji Seikaファルマ株式会社, Meiji Seika Faruma Kabushiki gaisha), formerly Meiji Seika Kaisha, Ltd. (明治製菓株式会社, Meiji Seika Kabushiki-gaisha) is a Japanese pharmaceutical company. It is currently a subsidiary of Meiji Holdings and a Japanese leader in the area of infectious … See moreSee details»
Corporate Profile - Meiji Holdings
Meiji Seika Pharma, as the top supplier of two out of the above four drugs, is advancing domestic production, from APIs to finished products, to ensure a stable supply in Japan.See details»
Pharmaceuticals | Meiji Group
Meiji Seika Pharma Co., Ltd. Beginning with the production of penicillin in 1946, Meiji Seika Pharma has established itself as a leader in the manufacture and sale of antibacterial drugs. …See details»
Corporate Profile - Meiji Holdings
Wide variety of disorders, and improving access to pharmaceutical products. Moreover, while developing our business, we will contribute to solving social issues by "promoting integrated …See details»
Meiji Seika Pharma Company Profile 2024: Overview
Feb 25, 2022 · Manufacturer of medicines intended for the treatment of infectious diseases. The company's portfolio includes antibiotics and vaccines for the …See details»
Meiji Seika Pharma - Crunchbase Investor Profile
Meiji Seika Pharma engages in the manufacturing and sales of ethical pharmaceuticals, agricultural chemicals and veterinary drugs.See details»
Meiji Seika ファルマ - Wikipedia
Meiji Seika ファルマから北上工場（岩手県 北上市）の移管を受けた上で農薬を生産していたが、農薬事業のMMAGへの譲渡に伴い、2022年1月4日付で三井化学アグロへ全株式を譲渡。商 …See details»
Meiji Seika Pharma Co., Ltd., Japan - AMR Industry Alliance
The AMR Industry Alliance brings together biotech, diagnostics, generics and research-based pharmaceutical companies, to drive and measure industry progress to curb antimicrobial …See details»
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Nov 14, 2024 · The combination of ARCALIS' advanced technology and operations in mRNA pharmaceuticals and vaccines with Meiji Seika Pharma's expertise in manufacturing, post …See details»
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Meiji Seika Pharma plans to supply the domestically produced next-generation sa-mRNA vaccine (replicon) ‘KOSTAIVE® for Intramuscular Injection’ in December 2024. This vaccine will be …See details»
Meiji Seika Pharma to Expand CMO Business with India …
Nov 9, 2021 · On November 8, Japan’s Meiji Seika Pharma invested $20.1 million to build a manufacturing site in India. According to the company, the move will boost the production capacity of its contract manufacturing organization …See details»
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Nov 14, 2024 · This investment will further strengthen the collaborative relationship between the two companies. The combination of ARCALIS' advanced technology and operations in mRNA …See details»
Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo
Nov 28, 2023 · The Japanese government on November 28 granted approval to Meiji Seika Pharma’s COVID-19 vaccine Kostaive and an updated version of Daiichi Sankyo’s jab …See details»
Infectious Diseases | Meiji Group
Meiact, an antibiotic drug first approved in Japan in 1994, has become widely prescribed globally. Later clinical trial data compiled by Meiji Seika Pharma found Meiact to be effective against …See details»
Meiji Seika ファルマからARCALIS社への出資に関するお知らせ
Nov 14, 2024 · Meiji Seika ファルマについて Meiji Seika ファルマは、1946年にペニシリンの製造・研究を開始して以来、感染症治療薬やワクチン、中枢神経疾患治療薬、ジェネリック医 …See details»
Meiji Seika Pharma Co., Ltd. - Drug pipelines, Patents ... - Patsnap
Explore Meiji Seika Pharma Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 52 clinical trials, 57 news, and 145 literature, Disease Domain:Infectious Diseases, Nervous …See details»
Meiji Seika Pharma Receives Manufacturing and Marketing …
Meiji Seika Pharma obtained exclusive rights to distribute Kostaive™ (ARCT-154)_ in Japan from CSL Seqirus on April 11, 2023, and is collaborating with ARCALIS, Inc. to establish integrated …See details»
Japan's Ministry of Health, Labour and Welfare Approves CSL and ...
Nov 28, 2023 · Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval. With the approval of ARCT-154, CSL now offers an even more comprehensive portfolio of …See details»
新型コロナウイルス感染症に対する次世代mRNAワクチン（レプ …
Meiji Seika ファルマ株式会社（本社：東京都中央区、代表取締役社長：小林大吉郎） は、新型コロナウイルス感染症に対する次世代mRNAワクチン(レプリコン)「コスタイベ筋 注用 …See details»
Persistence of Immune Response of Kostaive™, Self ... - Meiji …
Feb 5, 2024 · Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that persistence of immune …See details»